Today: 29 April 2026
Browse Category

NSE:VEDL 29 October 2025 - 10 December 2025

Vedanta Share Price Today: Q2 FY26 Results, Demerger Timeline, Analyst Targets and Key Risks (10 December 2025)

Vedanta Share Price Today: Q2 FY26 Results, Demerger Timeline, Analyst Targets and Key Risks (10 December 2025)

Vedanta Limited traded near ₹528 on 10 December 2025, close to its 52-week high, after posting record Q2 FY26 EBITDA of ₹11,612 crore. Net profit for the quarter fell 38% year-on-year to ₹3,479 crore. The stock is up over 40% from its 52-week low, with a dividend yield around 8–9%. High trading volumes and institutional activity continue amid ongoing regulatory scrutiny and short-seller allegations.
10 December 2025
··
Vedanta Limited Share Price Today: De‑merger, Incab Deal and Analyst Targets Shape VEDL’s 2026 Outlook

Vedanta Limited Share Price Today: De‑merger, Incab Deal and Analyst Targets Shape VEDL’s 2026 Outlook

Vedanta Limited traded near ₹525.5 on the NSE late morning 5 December 2025, down about 1% from the previous close. The stock touched a 52-week high above ₹540 on 4 December, lifted by progress on its $20 billion de-merger and a new power cables acquisition. Investors remain cautious over high debt, commodity price swings, and pending regulatory approvals. Market cap stands near ₹2.1 lakh crore.
5 December 2025
·
Vedanta Share Price Today Near Record High: Q2 FY26 Results, Demerger Delay and Analyst Forecasts Explained (1 December 2025)

Vedanta Share Price Today Near Record High: Q2 FY26 Results, Demerger Delay and Analyst Forecasts Explained (1 December 2025)

Vedanta Limited traded near a record high at ₹533–535 on the NSE as of late morning 1 December 2025, after reporting all-time high Q2 revenue of ₹39,218 crore and EBITDA of ₹11,612 crore. Net profit fell sharply due to large exceptional items, and the company’s demerger timeline has slipped into 2026. Shares are up about 24% over three months. Market cap stands near ₹2.06 lakh crore.
1 December 2025
·
Vedanta’s Big Split Stumbles: Govt Roadblocks, Fresh Delays & What It Means for Investors

Vedanta’s Big Split Stumbles: Govt Roadblocks, Fresh Delays & What It Means for Investors

India’s SEBI has approved key documents for Vedanta Ltd’s demerger, but final clearance depends on the National Company Law Tribunal, which delayed its hearing to November 12 after a bench reconstitution. The government has raised objections, alleging Vedanta altered the scheme and concealed liabilities. The demerger deadline has shifted to March 2026. Vedanta shares remain near a 52-week high despite the delays.
29 October 2025
··
1 2

Stock Market Today

  • TSX Picks: Aecon Group, Savaria Among Undervalued Stocks with Upside Potential
    April 29, 2026, 9:24 AM EDT. Investors eye undervalued TSX stocks amid volatile fuel prices and steady interest rates. Aecon Group (TSX:ARE), a CA$3.36 billion construction firm, trades 24.8% below estimated fair value, boosted by rising Q1 sales and a strong project pipeline. Savaria Corporation (TSX:SIS), specializing in accessibility solutions with a CA$2.15 billion market cap, is down 32.2% against fair value. Both companies show promising earnings growth projections, potentially rewarding investors as market conditions stabilize. These stocks highlight opportunities found through cash flow-based valuation methods amid an uncertain economic backdrop.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop